

## REVIEW ARTICLE

**Mechanism of Narcotic Addictions and Its Treatment by Medicinal Plants: A Detailed Review**Maryam Aftab<sup>1</sup>, Faheem Ullah<sup>2\*</sup>, Fatima Javed<sup>3</sup>, Naseer Ali Shah<sup>1</sup>, Zuratul Ain Abdul Hamid<sup>4</sup>**SUMMARY**

Drugs such as heroin, methamphetamine, cocaine, cannabis, alcohol, and opioids are examples of substances that have the potential to cause substance abuse and addiction. This is since each of these chemicals has a distinct mechanism of action to increase levels of dopamine and produce euphoria. To battle the effects of these narcotics, the primary focus of this review is on medicinal herbs that offer anti-narcotic qualities. The utilization of medicinal plants as a method for the treatment of substance abuse disorders has been a component of traditional medicine for some centuries. These natural antinarcotic compounds have the potential to be employed in an effective and risk-free manner to treat addiction. A class of substances known as phytochemicals has the potential to be utilized in the treatment of addiction. The development of appropriate treatment solutions that are effective over the long term is getting more challenging as a result of the fact that there is still a lack of study on the neurobiology of addiction.

**Keywords:** *Narcotics, Medicinal, Opioids, Plants, Reward Narcotics Syndrome.*

**How to cite this:** Aftab M, Ullah F, Javed F, Shah NA, Abdul Hamid ZA. Mechanism of Narcotic Addictions and Its Treatment by Medicinal Plants: A Detailed Review. *Life and Science*. 2025; 6(1): 122-132. doi: <http://doi.org/10.37185/LnS.1.1.448>

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.

(<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited.

**Introduction**

Narcotics are drugs that are considered to be harmful because they induce an effect on the brain and spinal cord that results in euphoria. The repeated use of these substances results in psychological and physical dependence. The Ventral Tegmental Area (VTA) is one of the brain's regions involved in the mesolimbic reward system. It projects to the Nucleus

<sup>1</sup>Department of Biosciences

COMSATS University Islamabad, Pakistan

<sup>2</sup>Department of Biological Sciences

National University of Medical Sciences (NUMS) Rawalpindi  
Pakistan

<sup>3</sup>Department of Chemistry

Shaheed Benazir Bhutto Women University Peshawar, Pakistan

<sup>4</sup>School of Materials and Mineral Resources Engineering  
Universiti Sains Malaysia, 14300, Nibong Tebal, Pulau Pinang  
Malaysia

Correspondence:

Dr. Faheem Ullah

Assistant Professor, Biological Sciences

National University of Medical Sciences (NUMS) Rawalpindi,  
Pakistan

E-mail: [faheemullah52@yahoo.com](mailto:faheemullah52@yahoo.com)

Received: July 25, 2023; 1<sup>st</sup> Revision Received: Mar 01, 2024

2<sup>nd</sup> Revision Received: May 13, 2024; Accepted: Jun 10, 2024

Accumbens (NAc), the Prefrontal Cortex (PFC), the Amygdala (AMY), and the Hippocampus (HPC of the brain).<sup>1</sup> Dopamine acts as a neuromodulator; it modifies the sensitivity of other neurotransmitters. In individuals who are addicted to opioids, the excessive dopamine signaling causes a change in the expression of the genetic code, which ultimately results in maladaptive changes in the brain. Burst release of dopamine is responsible for the development of long-term memories associated with the stimulation of reward; a tonic release of dopamine is associated with the urge to respond to similar signals. Consuming narcotics regularly leads to a reduction in the expression of dopamine receptors in the brain, which results in a diminished interest in activities.<sup>2</sup>

Opioids, cocaine, cannabis, alcohol, heroin, and methamphetamine are all addictive substances. Although they target different neurological

pathways, these chemicals typically raise dopamine levels, which induces euphoria. The traditional approaches to treating narcotics addict individuals are ineffective, and new methods must be investigated to treat patients.<sup>3,4</sup>

This review provides an in-depth analysis of addiction, the numerous stages of addiction, and reward deficiency syndrome. It examines how drugs that are deemed harmful induce euphoria and addiction through their impact on the body's physiological processes. Based on this review, it is possible that in the future, individuals who have become habituated to drugs could be treated using medicinal plants. Antinarcotics has the potential to cure narcotic addiction; but in order to ensure that patients successfully adhere to therapy, innovative delivery methods are required. Appropriate treatment for the physiological and psychological aspects of opioid addiction requires the utilization of multidisciplinary techniques.<sup>5</sup>

#### Reward Deficiency Syndrome and Addiction

The brain reward center consists of VTA, NAc, and SN. Dopamine is the principal neurotransmitter that activates this reward center, leading to euphoria. The repeated stimulation of dopaminergic neurons and the high rate of metabolism result in dopamine depletion, which leads to the dysphoric effects of substance abuse craving, as shown in figure 1. These disruptions in neurochemicals by narcotics are consistent with physical addiction. At the mesolimbic brain region, neurotransmitter interaction induces the reward where dopamine serves as an anti-stress neurotransmitter and interacts with D-2 dopamine receptors in the NAc (reward site). The cascade of neurotransmitters controls the reward system; the serotonin release causes the stimulation of enkephalins, which inhibits the Gamma-Amino butyric acid (GABA) at SN and VTA; GABA is responsible for the release of dopamine at the NAc. The brain of an addictive individual needs dopamine, and a decrease in dopamine release makes an individual at risk for multiple addictive, compulsive, and impulsive attitudes.<sup>6</sup>




Fig.1: Dopamine Depletion and reward deficiency Syndrome (NAc; Nucleus Accumbens, VTA Ventral Tegmental area, SN; Substantia Nigra)

#### Stages of Addiction

Addiction usually occurs in three different stages: (1) recreational phase, administration of the narcotics is occasional; (2) intensified/sustained drug use, habitual use of narcotics; and (3) addiction: intake of the narcotics becomes the principal activity for person.

Narcotic reinforcement is due to dopamine in NAc, VTA region, substantia nigra compacta, and dorsal striatum. Addiction is a pathological condition that reflects reward deficiency syndrome, stress, and functional deficiency. The dysfunction of cognitive behavior during addiction is visualized in the following stages: formation of preferences by the decision-making options, implementation of choice by motivation, self-regulation, and the inhibitory processes, and by process of feedback implication.<sup>7</sup> This review covers the mechanism of addiction induced by narcotics, including opioids, cocaine, cannabis, alcohol, heroin, and methamphetamine.<sup>8</sup>

#### Narcotics (Substances Responsible for Addiction)

Narcotics include illicit drugs and street drugs; the pharmacological effects of these abusive

drugs include physical dependence, tolerance, and addiction.<sup>9</sup> Narcotics responsible for

addictive potential include opioids, cannabis, methamphetamine, alcohol, cocaine and

**Table-1: Pathophysiological effects of Narcotics on different regions of brain**

Narcotics	Induced effect	Brain region alterations	References
Opioids	Increases dopamine release in the striatum and PFC	NAc, brain stem, chemoreceptor trigger zone (CTZ)	10
Cocaine	Dopaminylation on histone H3 glutamine in mid-brain	Mesocortico-limbic system (NAc and VTA)	11
Cannabis (marijuana)	Endocannabinoid system (cannabinoid receptors)	Cerebellum, Striatum (decreased dopamine synthesis)	12
Alcohol	Down-regulation of GABA- type A receptors and the upregulation of NMDA receptors.	Mid-brain, PFC.	13
Heroin	Alteration in the thalamocortical network and impairment of cognitive function.	Dysfunction of PFC region	14
Methamphetamine (ice)	Increased motor activity, neurotoxicity and impairment in memory	Increased dopamine release in NAc	15

heroin. The effects produced by Narcotics on different regions of the brain are mentioned in the table.1 below.

### Opioids

The opioid derived from opium poppy *Papaver somniferum* used for treatment of pain and hedonic effects, morphine is a common example. Other examples include codeine, heroin, hydromorphone, oxycodone, and fentanyl. Opioids are potent analgesics but induce addiction. Opioids affect the brain stem which regulates heart rate, breath rate, and sleep, it leads to depressed breathing and even death.<sup>16</sup> By long-term opioid use, adaptive changes occur at the cellular level, which promotes tolerance that induces dependence, and upon cessation withdrawal symptoms appear. At systematic level, distinct processes are required for the possession of analgesia,

tolerance, and dependence. Prescription opioids include both natural, semisynthetic (codeine and morphine) and synthetic opioids (methadone, tramadol, and fentanyl). Some synthetic opioids such as fentanyl, are prepared and distributed illegally.<sup>17</sup>

### Opioid Receptors

Opioid receptors, G-protein coupled receptors, present in the brain, spinal cord, gastrointestinal tract, and skin. Their stimulation results in brain sedation, analgesia, euphoria, and respiratory depression. Among chronic opioid user's tolerance and dependence develop rapidly, while diarrhea, bone aches, and goose bumps develop as withdrawal symptoms appear. The opioid receptors are linked with reward processing. Alterations in opioid receptor sensitivity are linked to the evaluation of opioid dependence, especially when the patient is

receiving treatment against narcotics.<sup>18</sup> When opioids bind to opioid receptors, a number of cytoplasmic reaction cascades are eventually triggered, including activation of phospholipase C, inhibition of adenylyl cyclase, activation of potassium channels, and closure of voltage-gated calcium channel for inhibition of neurotransmitters. Three classical opioid receptors distributed in the PNS and CNS are the mu-opioid receptor, delta opioid receptor, and kappa opioid receptor, as shown in figure 2. Mu-opioid receptors are found in the cerebral cortex and thalamus; they possess an affinity for endorphins and induce euphoria, physical dependence, and respiratory depression. The mu-opioid receptors are distributed in NAc and basolateral amygdala. They are typically involved in the brain reward system, and their effect changes with age, particularly during




Fig.2: Euphoria induced by the activation of Opioid receptors

adolescence. The kappa-opioid receptors located in the hypothalamus bind to dynorphins, stimulate anti-reward action, and induce sedation. Prolonged exposure to illicit drugs increases kappa-opioid receptor function by stimulation of corticotrophin-releasing factor that promotes relapse. The stress induced by long-term drug exposure can produce a depressant effect. The delta-opioid receptors present in basal ganglia bind to enkephalins and produce anxiolytic actions; their activation decreases anxiety levels and reduces depression symptoms. Opioid antagonists reverse the opioid effect by binding at opioid receptors.<sup>19</sup>

### Cocaine

Cocaine is a psychostimulant and illicit drug used in America, Western Europe, and Australia. Genetic and environmental factors contribute to

the development of cocaine use disorder. Use of cocaine, both acute and chronic, changes epigenetic expression, leading to alterations in neuronal adaptations and brain circuits that are associated with cocaine dependence. Cocaine blocks the reuptake of dopamine, serotonin, and noradrenaline, resulting in increased levels of these neurotransmitters at the synaptic cleft. The euphoric effects of cocaine are attributed to the increased dopamine in the limbic system. Chronic cocaine use leads to changes in the neurotransmitter system and the functioning of various brain circuits, including the mesocortical limbic system (NAc and VTA).<sup>20</sup>

By cocaine exposure dopamine accumulates in neurons of VTA, association of dopamine within chromatin initiate an epigenetic regulation called Dopaminylation. The histone H3 glutamine 5-dopaminylation is critical for cocaine-induced transcriptional changes in the midbrain, as shown in figure 6. Rats suffering from cocaine withdrawal showed an accumulation of H3 glutamine 5-dopamine in the VTA producing impact on the function of VTA.<sup>21</sup>

### Alterations in the Gene Expression Level

The gene expression level analyzed among cocaine abusers in postmortem brain and samples found that some of the genes expressed differentially by the transcription regulation, as shown in table-2 below. The gene expression changes in the PFC were assessed in two studies analyzing postmortem samples of dorsolateral and anterior PFC among cocaine abusers. The alteration in gene expression in the anterior PFC among cocaine, cannabis, and phenyl-cyclidine abusers reflects the genes linked to calmodulin functioning, golgi, and endoplasmic reticulum-related genes. The genes involved in mitochondrial function and oligodendrocyte function in the dorsolateral PFC are mutated in cocaine abusers.<sup>22</sup> Gene expression is altered in cocaine abusers, affecting myelin and glial function-related genes in the NAc. The PLP-1 gene, which encodes the major component of myelin, is also altered. In the hippocampus, gene expression changes occur in cellular and mitochondrial functional genes, as well as genes involved in neurogenesis. Dopaminergic cells in the midbrain of cocaine abusers show altered gene expression levels, impacting metabolic

**Table-2: Brain regions involved and particular gene mutation during cocaine addiction**

Brain region involved	Addiction source	Gene mutation	References
Dorsolateral PFC	Cocaine abusers	Mitochondrial genes, Genes for oligodendrocyte function	23
Anterior PFC	Cannabis and phenyl-cyclidine abusers	Calmodulin functioning, Golgi and endoplasmic reticulum-related genes	24
NAc	Cocaine abusers	Glial function genes, PLP-1 gene, and myelin-related genes, Increased expression of PLCB-1	25,26
Hippocampus	Cocaine	Cellular and mitochondrial functioning genes and genes involved in neurogenesis were altered, KTD20 gene altered	27
Midbrain	Cocaine	Genes involved in dopamine metabolism altered	28

cascade and neuronal differentiation. Neuronal progenitor cells also experience altered gene expression, affecting genes involved in immune and inflammatory processes. Convergent analysis of studies performed on animals and human gene expression among cocaine abusers reveals alterations in ERK/MAPK signaling pathway genes, genes involved in dopamine and serotonin function (slc1a2, aldo, ald, calm3, and eno2), and genes involved in brain plasticity (APP, KCNA2, GRIN2A, GRIN2B, MAP4, SNCB, PCDH10, SV2C, and PPP3CA). Acute exposure to cocaine increases NFAT transcription through the upregulation of NFAT5, a transcription factor in dopaminergic neuronal cells. Cocaine exposure leads to the downregulation of microRNAs mir-9, mir-153, and mir-124, which are responsible for cocaine dependence. The PLCB1 protein (phospholipase c beta 1) possesses genetic variations linked to cocaine dependence, and its expression is increased in the NAc of cocaine abusers.<sup>29</sup>

### **Cannabis (Marijuana)**

Cannabis addiction is linked to reward, emotional regulation, cognitive behavior, and stress through interaction with cannabinoid receptors. Cannabis use is a pathological disorder with a genetic basis in adolescents and individuals associated with psychiatric disorders. Marijuana acts on the endocannabinoid system, modulating behavioral, endocrine, immune, cognitive, and motor

functions. Genetic factors, sex, and environment influence cannabis use disorder, and the neurobiological mechanisms of addiction correspond to increased drug craving, anxiety, and negative withdrawal effects. Certain epigenetic changes contribute to neurobiological changes associated with molecular and cellular processes linked to cannabis addiction. Preclinical investigations of human brain structure are limited, but the cerebellum shows differences after cannabis use disorder. Cannabis use is known to cause depression, particularly among girls, as well as anxiety, psychological problems, and suicidal thoughts, as shown in figure 7. Impairment in the opioid genes potentiates effects on cognition and emotions, similar to findings of prenatal cannabis exposure in animals, which causes alterations in the limbic encephalic system.<sup>30</sup>

### **Cannabis-Related Changes in Neurotransmitters**

Cannabis use disorder is developed by chronic neuroadaptations produced by repeated use. The delta-9-tetrahydrocannabinol (THC) induces euphoria, which is responsible for addiction.<sup>31</sup> The THC increases dopamine release in the striatum of individuals addicted to cannabis. Long-term use, on the other hand, decreases dopamine levels, which is linked to decreased attention, increased negative



symptoms, and severe addiction. In addition to abuse drugs, the function of striatal dopamine receptors D-2 and D-3 is decreased. However, in cannabis addicted individuals, the dopamine receptors are normal, resulting in unique dopamine transmission. The transmission of glutamate is regulated by endocannabinergic receptors (CB1RS), and the level of glutamate increases after acute cannabis use, which is important for inhibitory control and drug-taking behavior. However, after chronic cannabis use, the level of glutamate falls in different brain regions. This disturbs synaptic functioning in the pre-frontal motor cortex and disrupts normal brain development, contributing to drug craving.<sup>32</sup>

### **Alcohol**

Alcohol use can be developed into abusive behavior and addiction, it is a psychiatric disorder that leads to severe health consequences. The neurobiological mechanism for alcohol addiction develops in response to environmental and genetic stimuli. Environmental factors also contribute to the development of alcohol addiction, these include exposure to different drugs, alternate reward behavior, stressful lifetime events, hopelessness, anxiety, depression, and adverse reinforcement effects of psychoactive drugs.<sup>33</sup>

### **Pathophysiology of Alcohol Use Disorder**

Alcohol is the CNS depressant; it elevates gamma-aminobutyric acid (GABA) and inhibits postsynaptic n-methyl-d-aspartate (NMDA) glutamate receptors. Prolonged alcohol use, at high levels, down-regulation of GABA type A receptor and upregulation of NMDA receptors occurs. Abrupt cessation of alcohol in the blood unmasks the glutamate-mediated excitation and produces delirium. The inhibition of the GABA system in the brain stem leads to seizure development. Alcohol withdrawal causes hyperarousal and hallucinations due to an increase in dopamine levels. The stimulation of GABA type A receptor induces hyperpolarization effects on the membrane by increasing the influx of chloride ions, causing sedation, anxiolysis, and

anticonvulsant action. Alcohol addiction can be broadly divided into different stages: craving, misuse of substance, drunkenness, withdrawal, abrupt withdrawal, recovery, and prevention of relapse. The underlying addiction mechanism involves the release of dopamine in the reward pathway that connects the mid-brain to the PFC, and by the sudden release of dopamine, euphoria develops.<sup>34</sup>

The slow decrease in alcohol consumption, planned intervention with medicines and ultimately complete stop can decrease harmful effects of alcohol withdrawal. The agents target the GABA type A receptor and can support detoxification (examples are benzodiazepines, barbiturates, and propofol).<sup>35</sup>

### **Heroin**

Addiction characterized by compulsory attitude toward the use of drugs and an emergent negative emotional state. The important aspect of heroin addiction is pathological memory related to modulated synapse transmission and neuroplasticity. Chronic heroin users experience impairment of cognitive function, which leads to disturbances in learning, memory, and functional losses. The dysfunction of the PFC contributes to uncontrolled use of heroin.<sup>36</sup>

### **Disturbed Nuclear Signaling Related to Heroin**

The addictive behavior for heroin addiction seizes the normal memory in the brain circuit at the transition from drug-taking behavior to the compulsory intake of heroin. The abrupt dopamine release from VTA to the NAc and glutamate release from the basolateral area to NAc serves to be the main pathway for the mediation of conditioned cues including the restoration of heroin intake as shown in figure.3. The dorsolateral striatum, NAc, and dorsal hippocampus play an important role in the restoration of drug-taking behavior. The subdivisions of medial PFC target NAc for relapse and reflect the vital implication for which pharmacological therapies could be more beneficial.<sup>36</sup>

### **Methamphetamine**

Methamphetamine is a transparent white

crystalline powder, soluble in water and bitter. Methamphetamine is a member of amphetamine-type stimulants having a long duration of action and increased potential to cross BBB. The non-pharmacological use of amphetamines is at high doses and administered other than the oral route (includes intranasal, intravenous, intramuscular, vaginal, and rectal route). Amphetamine is used for relaxation and for night-shift employers to enhance performance. The regular use of amphetamine is more complex than that of occasional use, and it leads to substance use disorder development.<sup>37</sup>

### Sensitization induced by Methamphetamine

The repeated use of methamphetamine leads to increased motor activity and sensitivity; this process is termed sensitization, as shown in the figure.4 below. The continuous use of amphetamine can raise the dopamine level in Nac. Methamphetamine enters into dopaminergic pre-synapse by the dopamine transporter and promotes its release in the cytosol, and cytosolic dopamine level is raised by the vesicular monoamine transporter 2. Methamphetamine possesses the potential to inhibit the monoamine oxidase enzyme involved in the metabolism of dopamine and ultimately contributes to the behavioral deficit, amnesia, and neurotoxicity in CNS. Methamphetamine activates the brain reward pathway by activating dopamine receptors and increasing dopaminergic signaling in the brain reward pathway.<sup>38</sup>

### Medicinal Plants

Addiction to narcotics is a major psychiatric and socio-economic issue in society. As the person is diagnosed with narcotic addiction, it becomes mandatory to bring the patient back to life. For centuries, man used medicinal plants for their pharmacological value, which plays an important role in treating different diseases. The phytochemicals (including alkaloids, flavonoids, terpenoids, and phenylpropanoids) present in medicinal plants possess biological activities that can upgrade the quality of human life in the pharmaceutical industries.<sup>39</sup>

### Nigella Sativa

*Nigella sativa* is a non-opiate drug that belongs to the family Ranunculaceae and is effectively used




Fig.3: Effects of heroin addiction




Fig.4: Sensitization induced by Methamphetamine

for the treatment of withdrawal symptoms. Its common name is 'kalonji', known as 'habatul saud', also called black cumin. *Nigella sativa* is effective for the long-term treatment of opioid dependence and for the treatment of infections. The majority of addicts suffer from infections, so it is more effective for the treatment of addiction. It is rich in nutritious amino acids, by which opioid addicts get more benefits, especially those who require nutritious supplements.<sup>40</sup>

### Withania Somnifera

*Withania somnifera* known as ashwaganda, belongs to the family Solanaceae, used for the treatment of benzodiazepine withdrawal syndrome as it possesses GABA receptor agonist activity. It is effective for the relief of over-active nervous system and anxiety linked to withdrawal syndrome. The methanol extract of *W. somnifera* is effective for neural regeneration and synapse reconstruction potential and relieves the withdrawal effects of morphine. The morphological changes induced by opioid withdrawal in NAc can be prevented upon treatment with *Somnifera* extract.<sup>41</sup>

### Matricaria Recutita

*Matricaria recutita* belongs to the family Asteraceae. The phytochemicals are terpenoids, flavonoids, coumarins, and spiro ethers. It possesses benzodiazepine-like ligands and

certain inhibitory effects which inhibit morphine dependence. The benzodiazepine-like compounds of *M. recutita* act on the gamma-aminobutyric acid (GABA type receptors, increasing the GABA effect on ligand-gated ion channel, causing hyperpolarization of neurons, decreasing the neuronal response accompanied by low action potential firing, leading to sedative effect.<sup>42</sup>

### **Salvia Officinalis**

*Salvia officinalis* exerts different pharmacological actions on CNS, including neuroprotective, antioxidant, analgesic, and memory-enhancing effects. Its flavone components can stimulate the chloride channels of GABA receptors, which are responsible for the anti-addiction potential. It possesses anti-inflammatory and anti-oxidant action. When administered to morphine-dependent rats, hydro-alcoholic extract of *S. officinalis* at doses of 400 mg/kg, 600 mg/kg, and 800 mg/kg was found to be efficacious in eliciting anti-opioid effects.<sup>43</sup>

### **Mitragyna Speciosa**

*Mitragyna Speciosa* belongs to the Rubiaceae family, and its common name is ketum (biak). In southeast Asia, it is used for the treatment of pain, cough, and diarrhea and it acts as a stimulant to enhance efficiency. It possesses stimulant action at low doses and opioid-like effects at high doses. It is used in the United States as a cost-effective alternative to the self-withdrawal treatment of opioids. Kratom is used with *o*-desmethyl-tramadol, marketed as krypton, and can be added to synthetic cannabinoids. The phytochemicals of kratom are mitragynine and 7-OH-mitragynine which possess opioid-like actions and as partial agonists at mu-opioid receptors and competitive antagonists at kappa and delta opioid receptors. The partial agonist activity of mu-opioid receptors reduces respiratory depression in the case of overdose. 7-OH-mitragynine is 13-46 times more potent than morphine and mitragynine, respectively. Mitragynine can stimulate the alpha two adrenergic receptors accent for the sedative, analgesic action without

causing respiratory depression. Mitragynine can produce effects on dopamine and serotonin receptors, and it could be used as maintenance therapy to treat addicted opioid individuals.<sup>44</sup>

### **Albortisia Papuana Leaves**

*Albortisia papuana* l. commonly known as Mekai by the Dayak tribe. Due to its actions on CNS, its phytochemicals were analyzed to treat withdrawal symptoms of opioid addiction in the narcotic-dependent mouse model by psychomotor tests, light and ear nerve sensitivity tests, curiosity tests, and coordination tests. *A. papuana* l. proved to reduce withdrawal effects and could be used for rehabilitation in morphine addicts.<sup>45</sup>

### **Terbenthe Iboga**

Terbenthe Iboga belongs to the family Apocyanaceae, used as traditional medicine for the treatment of opioid withdrawal. *T. iboga* possesses a high fraction of ibogaine alkaloids, which showed anti-addictive effects against several abusive drugs. It is a noncompetitive antagonist at nicotinic acetylcholine receptors. Pre-clinical data demonstrates decreased self-administration of morphine, cocaine, alcohol, nicotine, and methamphetamine in different animal models. In clinical settings, Ibogaine reduces craving and withdrawal from narcotics in humans.<sup>46</sup>

### **Corydalis Species**

The *Corydalis* sp. belongs to the family Papavaraceae and it possesses alkaloids, coumarins, flavonoids, steroids, organic acids, and certain other chemical moieties. The protoberberine alkaloids possess analgesic, antitumor, antipsychotic, and antiplatelet action. They exert pharmacological action on the nervous, cardiovascular, and digestive systems. The most pronounced effect of *Corydalis* sp. is analgesia and it does not produce addiction and tolerance.<sup>47</sup>

### **Conclusion**

The biggest indicator of addiction potential is the euphoria that narcotics provide. The brain regions are altered in addicted individuals and they are responsible for the tangled condition of addicted individuals. Although they have



different mechanisms of addiction, the activation of the brain's reward system and a rise in dopamine levels are the results. As medication therapy is effective in treating addicted individuals, relapse is still a complicated situation that occurs due to the neurological changes in the brain signaling cascade and the tolerance developed due to repeated use of narcotics. The conventional method of treating narcotic-dependent individuals may be substituted by the use of medicinal plants with no side effects and patient adherence to treatment could be elevated.

**Acknowledgment:** This research work is supported by the National University of Medical Sciences, NUMS, Rawalpindi, under the Institutional Research Fund (IRG-Grant # 22012).

**Conflict of Interest:** None

**Grant Support and Financial Disclosure:** NUMS

## REFERENCES

- Wei L, Wu GR, Bi M, Baeken C. Effective connectivity predicts cognitive empathy in cocaine addiction: a spectral dynamic causal modeling study. *Brain Imaging and Behavior*. 2021; 15: 1553-61. doi: 10.1007/s11682-020-00354-y
- Wise RA, Robble MA. Dopamine and addiction. *Annual review of psychology*. 2020; 71: 79-106. doi:10.1146/annurev-psych-010418-103337
- Wemm SE, Sinha R. Drug-induced stress responses and addiction risk and relapse. *Neurobiology of stress*. 2019; 10: 100148. doi: 10.1016/j.ynstr.2019.100148
- ULLAH F, OTHMAN MBH, JAVED F, AHMAD Z, AKIL HM. Classification, processing and application of hydrogels: A review. *Materials Science and Engineering: C*. 2015; 57, 414-33.
- Roberts BM, Lopes EF, Cragg SJ. Axonal modulation of striatal dopamine release by local  $\gamma$ -aminobutyric acid (GABA) signalling. *Cells*. 2021; 10: 709. doi: 10.3390/cells10030709
- Villiamma P, Casby J, Groman SM. Adolescent reinforcement-learning trajectories predict cocaine-taking behaviors in adult male and female rats. *Psychopharmacology*. 2022; 239: 2885-907. doi: 10.1007/s00213-022-06174-w
- Qi L, Tian ZH, Yue Y, Guan S, Tang L, Dong G. Effects of acute exercise on craving and cortical hemodynamics under drug-cue exposure in MA-dependent individuals. *Neuroscience Letters*. 2022; 781: 136672. doi: 10.1016/j.neu.2022.136672
- Unterrainer HF, Hiebler-Ragger M, Koschutnig K, Fuchshuber J, Ragger K, Perchtold CM, et al. Brain structure alterations in poly-drug use: reduced cortical thickness and white matter impairments in regions associated with affective, cognitive, and motor functions. *Frontiers in psychiatry*. 2019; 10: 667. doi: 10.3389/fpsyt.2019.00667
- Bachmutsky I, Wei XP, Kish E, Yackle K. Opioids depress breathing through two small brainstem sites. *Elife*. 2020; 9: e52694. doi: 10.7554/eLife.52694
- Bender BN, Torregrossa MM. Molecular and circuit mechanisms regulating cocaine memory. *Cellular and Molecular Life Sciences*. 2020; 77: 3745-68. doi: 10.1007/s00018-020-03498-8
- Malabadi RB, Kolkar KP, Chalannavar RK, Baijnath H. Cannabis sativa: Difference between Medical Cannabis (Marijuana or drug type) and Industrial hemp. *GSC Biological and Pharmaceutical Sciences*. 2023; 24: 377-81. doi:10.30574/gscbps.2023.24.3.0393
- Kashem MA, Šerý O, Pow DV, Rowlands BD, Rae CD, Balcar VJ. Actions of alcohol in brain: genetics, metabolomics, GABA receptors, proteomics and glutamate transporter GLAST/EAAT1. *Current Molecular Pharmacology*. 2021; 14: 138-49. doi: 10.2174/1874467213666200424155244
- Liu S, Wang S, Zhang M, Xu Y, Shao Z, Chen L, et al. Brain responses to drug cues predict craving changes in abstinent heroin users: a preliminary study. *Neuroimage*. 2021; 237: 118169. doi:10.1016/j.neuroimage.2021.118169
- Hamel C, Corace K, Hersi M, Rice D, Willows M, Macpherson P, et al. Psychosocial and pharmacologic interventions for methamphetamine addiction: protocol for a scoping review of the literature. *Systematic reviews*. 2020; 9: 245. doi:10.1186/s13643-020-01499-z
- Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. *Harm reduction journal*. 2019; 16: 9. doi: 10.1186/s12954-019-0278-6
- Ganesh A, Maxwell LG. Assessing and Managing Opioid-Related Side Effects in Children and Adolescents. *Opioid Therapy in Infants, Children, and Adolescents*. 2020: 139-54. doi: 10.1007/978-3-030-36287-4\_10
- Li X, Li B, Zhang J, Chen T, Wu H, Shi X, et al. Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis. *Medicine*. 2021; 100: e24361. doi:10.1097/MD.00000000000024361

18. Campos-Jurado Y, Igual-López M, Padilla F, Zornoza T, Granero L, Polache A, et al. Activation of MORs in the VTA induces changes on cFos expression in different projecting regions: Effect of inflammatory pain. *Neurochemistry International*. 2019; 131: 104521. doi:10.1016/j.neuint.2019.104521
19. Fernández-Castillo N, Cabana-Domínguez J, Corominas R, Cormand B. Molecular genetics of cocaine use disorders in humans. *Molecular psychiatry*. 2022; 27: 624-39. doi: 10.1038/s41380-021-01256-1
20. Lepack AE, Werner CT, Stewart AF, Fulton SL, Zhong P, Farrelly LA, et al. Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking. *Science*. 2020; 368: 197- 201. doi:10.1126/science.aa w8806
21. Ravindran P, Jayanthi S, Sivaraman AK, Dhanalakshmi R, Muralidhar A, Vincent R. Proficient mining of informative gene from microarray gene expression dataset using machine intelligence. *Smart Intelligent Computing and Communication Technology*. 2021; 38: 417-22. doi: 10.3233/APC210076
22. Huggett SB, Stallings MC. Genetic architecture and molecular neuropathology of human cocaine addiction. *Journal of Neuroscience*. 2020; 40: 5300-13. Doi:10.1523/JNEUROSCI.2879-19.2020
23. Sullivan RM, Maple KE, Wallace AL, Thomas AM, Lisdahl KM. Examining inhibitory affective Processing within the Rostral Anterior Cingulate Cortex among Abstinent Cannabis-using adolescents and young adults. *Frontiers in Psychiatry*. 2022; 13: 851118. doi: 10.3389/fpsy.2022.851118
24. Egervari G, Kozlenkov A, Dracheva S, Hurd YL. Molecular windows into the human brain for psychiatric disorders. *Molecular psychiatry*. 2019; 24: 653-73. doi:10.1038/s41380-018-0125-2
25. Tejan-Kamara AZ. The immediate and persistent effects of binge ethanol exposure on myelin protein expression in DBA/2J mice. 2020. doi:10.25772/APSJ-HE14
26. Huggett SB, Stallings MC. Cocaine'omics: genome-wide and transcriptome-wide analyses provide biological insight into cocaine use and dependence. *Addiction Biology*. 2020; 25: e12719. doi: 10.1111/adb.12719
27. Tian G, Hui M, Macchia D, Derdeyn P, Rogers A, Hubbard E, et al. An extended amygdala-midbrain circuit controlling cocaine withdrawal-induced anxiety and reinstatement. *Cell reports*. 2022; 39: 110775. doi:10.1016/j.celrep.2022.110775
28. Pineda-Cirera L, Cabana-Domínguez J, Benetó N, Diez H, Arenas C, Cormand B, et al. DDC expression is not regulated by NFAT5 (TonEBP) in dopaminergic neural cell lines. *Gene*. 2020; 742: 144569. doi:10.1016/j.gene.2020.144569
29. Ferland JMN, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. *Nature Neuroscience*. 2020; 23: 600-10. doi:10.1038/s41593-020-0611-0
30. D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. *Lancet Psychiatry*. 2019; 6: 35-45. doi: 10.1016/S2215-0366(18)30427-9
31. Colizzi M, Weltens N, McGuire P, Lythgoe D, Williams S, Van Oudenhove L, et al. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. *Molecular psychiatry*. 2020; 25: 3231-40. doi: 10.1038/s41380-019-0374-8
32. Ahmed SH, Badiani A, Miczek KA, Müller CP. Non-pharmacological factors that determine drug use and addiction. *Neuroscience & Biobehavioral Reviews*. 2020; 110: 3-27. doi:10.1016/j.neubiorev.2018.08.015
33. Subramaniam V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, et al. Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. *Toxicology reports*. 2021; 8: 376-85. doi:10.1016/j.toxrep.2021.02.010
34. Ma B, Mei D, Wang F, Liu Y, Zhou W. Cognitive enhancers as a treatment for heroin relapse and addiction. *Pharmacological research*. 2019; 141: 378-83. doi:10.1016/j.phrs.2019.01.025
35. Tian Y, Wang D, Fan F, Yang Y, Fu F, Wei D, et al. Differences in cognitive deficits in patients with methamphetamine and heroin use disorder compared with healthy controls in a Chinese Han population. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2022; 117: 110543. doi: 10.1016/j.pnpbp.2022.110543
36. Kaviyani F, Khorrami M, Heydari H, Namvar M. Understanding the laps and relapse process: in-depth interviews with individual who use methamphetamine. *Substance Abuse Treatment, Prevention, and Policy*. 2023; 18: 41. doi:10.1186/s13011-023-00548-9
37. Huang J, Yang G, Li Z, Leung CK, Wang W, Li Y, et al. Involvement of dopamine D3 receptor and dopamine transporter in methamphetamine-induced behavioral sensitization in tree shrews. *Brain and Behavior*. 2020; 10: e01533. doi: 10.1002/brb3.1533

38. Koparde A, Doijad RC, Magdum C. Natural products in drug discovery. *Pharmacognosy-medicinal plants: IntechOpen*; 2019. doi: 10.5772/intechopen.82860
39. Hannan MA, Rahman MA, Sohag AAM, Uddin MJ, Dash R, Sikder MH, et al. Black cummin (*Nigella sativa* L.): A comprehensive review on phytochemistry, health benefits, molecular pharmacology, and safety. *Nutrients*. 2021; 13: 1784. doi: 10.3390/nu13061784
40. Mukherjee PK, Banerjee S, Biswas S, Das B, Kar A, Katiyar C. *Withania somnifera* (L.) Dunal-Modern perspectives of an ancient Rasayana from Ayurveda. *Journal of ethnopharmacology*. 2021; 264: 113157. doi:10.1016/j.jep.2020.113157
41. de Lima Dantas JB, Freire TF, Sanches AC, Julião EL, Medrado AR, Martins GB. Action of *Matricaria recutita* (chamomile) in the management of radiochemotherapy oral mucositis: A systematic review. *Phytotherapy Research*. 2022; 36: 1115-25. doi: 10.1002/ptr.7378
42. Pizani RS, Viganó J, de Souza Mesquita LM, Contieri LS, Sanches VL, Chaves JO, et al. Beyond aroma: A review on advanced extraction processes from rosemary (*Rosmarinus officinalis*) and sage (*Salvia officinalis*) to produce phenolic acids and diterpenes. *Trends in Food Science & Technology*. 2022; 127: 245-62. doi: 10.1016/j.tifs.2022.07.001
43. Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, et al. The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats. *Psychopharmacology*. 2019; 236: 2725-34. doi: 10.1007/s00213-019-05247-7
44. Obeng S, Crowley ML, Mottinelli M, León F, Gonzalez JD, Chen Y, et al. The *Mitragyna speciosa* (kratom) alkaloid mitragynine: Analysis of adrenergic  $\alpha_2$  receptor activity in vitro and in vivo. *European journal of pharmacology*. 2024; 980: 176863. doi:10.1016/j.ejphar.2024.176863
45. Shi Z, Pan S, Wang L, Li S. Oleanolic acid attenuates morphine withdrawal symptoms in rodents: association with regulation of dopamine function. *Drug design, development and therapy*. 2021: 3685-96. doi: 10.2147/DDDT.S326583
46. Krengel F, Chevalier Q, Dickinson J, Herrera Santoyo J, Reyes Chilpa R. Metabolite Profiling of Anti-Addictive Alkaloids from Four Mexican *Tabernaemontana* Species and the Entheogenic African Shrub *Tabernanthe iboga* (Apocynaceae). *Chemistry & Biodiversity*. 2019; 16: e1800506. doi: 10.1002/cbdv.201800506
47. Xu X, Wang D. Comparative chloroplast genomics of *Corydalis* species (Papaveraceae): evolutionary perspectives on their unusual large scale rearrangements. *Frontiers in Plant Science*. 2021; 11: 600354. doi: 10.3389/fpls.2020.600354

#### Authors Contribution

**MA:** Data collection, data analysis, manuscript writing and proofreading

**FU:** Idea conception, study designing, data analysis, results and interpretation, manuscript writing and proofreading

**FJ:** Idea conception, data analysis, results and interpretation

**SAS:** Manuscript writing and proofreading

**ZAH:** Data collection